Loading...
•
Mar 31
Teva Q1 2025 Earnings Report
Teva reported continued revenue growth in Q1 2025, supported by strong innovative product performance and stable generics business.
Key Takeaways
Teva delivered $3.9 billion in revenue for Q1 2025, achieving its ninth consecutive quarter of growth. The company posted an adjusted EPS of $0.52 and generated $107 million in free cash flow, driven by innovative portfolio performance and effective cost management.
Teva achieved its ninth straight quarter of revenue growth, totaling $3.9 billion.
Innovative products generated $589 million and each grew more than 25% year over year.
Free cash flow reached $107 million for the quarter.
Teva entered the Acceleration Phase of its Pivot to Growth strategy, reaffirming 2027 targets.
Teva
Teva
Forward Guidance
Teva revised its 2025 outlook while reaffirming its 2027 targets, focusing on innovation, operational efficiency, and transformation into a leading biopharma firm.
Positive Outlook
- Revised 2025 revenue guidance to $16.8–17.2 billion.
- Revised 2025 non-GAAP EPS guidance to $2.45–$2.65.
- Revised 2025 free cash flow guidance to $1.6–1.9 billion.
- Continued strong momentum in innovative medicines and biosimilars.
- Projected $700 million in net savings by 2027.
Challenges Ahead
- Significant indebtedness may limit financial flexibility.
- Exposure to geopolitical risks including war in Israel and Ukraine conflict.
- Potential litigation and regulatory risks in multiple jurisdictions.
- Execution risks in strategic transformation and divestiture plans.
- Macroeconomic uncertainties may impact operations and supply chains.